Search Results | Clinicalinfo

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 21 – 40 of 3231

Table A. Summary of IMPAACT P1066 Cohorts and Participation

https://clinicalinfo.hiv.gov/node/11154

Table B. Raltegravir Pharmacokinetic Parameters for Raltegravir-Naive and Raltegravir-Exposed Neonates

https://clinicalinfo.hiv.gov/node/11155

Table 17a. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Central Nervous System Toxicity

https://clinicalinfo.hiv.gov/node/11157

Table 17b. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Dyslipidemia

https://clinicalinfo.hiv.gov/node/11158

Table 17c. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Gastrointestinal Effects

https://clinicalinfo.hiv.gov/node/11159

Table 17d. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Hematologic Effects

https://clinicalinfo.hiv.gov/node/11160

Table 17e. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Hepatic Events

https://clinicalinfo.hiv.gov/node/11161

Table 17f. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Insulin Resistance, Asymptomatic Hyperglycemia, and Diabetes Mellitus

https://clinicalinfo.hiv.gov/node/11162

Table 17g. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Lactic Acidosis

https://clinicalinfo.hiv.gov/node/11163

Table 17h. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Lipodystrophies and Weight Gain

https://clinicalinfo.hiv.gov/node/11164

Table 17i. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Nephrotoxic Effects

https://clinicalinfo.hiv.gov/node/11165

Table 17j. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis

https://clinicalinfo.hiv.gov/node/11166

Table 17k. Antiretroviral Therapy–Associated Adverse Effects and Management Recommendations—Rash and Hypersensitivity Reactions

https://clinicalinfo.hiv.gov/node/11167

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

https://clinicalinfo.hiv.gov/node/11168

Fostemsavir (Rukobia, FTR)

https://clinicalinfo.hiv.gov/node/11170

Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive

https://clinicalinfo.hiv.gov/node/11173

Pre-exposure Prophylaxis (PrEP) to Prevent HIV During Periconception, Antepartum, and Postpartum Periods

https://clinicalinfo.hiv.gov/node/11175

https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/paciente

https://clinicalinfo.hiv.gov/drugs/cabotegravir-1/paciente

https://clinicalinfo.hiv.gov/node/11178